Regeneron announces start of REGN-COV2 phase 3 COVID-19 prevention trial
TARRYTOWN, N.Y. — Regeneron Pharmaceuticals announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron’s investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2’s ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient’s housemate), and is being run